A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
ILLUMINATE
Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents
1 other identifier
interventional
15,067
7 countries
221
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2004
Typical duration for phase_3
221 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2004
CompletedFirst Submitted
Initial submission to the registry
August 22, 2005
CompletedFirst Posted
Study publicly available on registry
August 24, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2007
CompletedFebruary 3, 2012
January 1, 2012
2.9 years
August 22, 2005
January 30, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
The time to first occurrence of a major cardiovascular disease event
Secondary Outcomes (1)
Various composites of major cardiovascular disease events and other lipid parameters
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events
You may not qualify if:
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (221)
Pfizer Investigational Site
Alabaster, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Modesto, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Santa Rosa, California, United States
Pfizer Investigational Site
Tustin, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Longmont, Colorado, United States
Pfizer Investigational Site
Guilford, Connecticut, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Coral Gables, Florida, United States
Pfizer Investigational Site
Fort Meyers, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jacksonville Beach, Florida, United States
Pfizer Investigational Site
Lakeland, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Port Charlotte, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Aurora, Illinois, United States
Pfizer Investigational Site
Blue Island, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Davenport, Iowa, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Witchita, Kansas, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
Marrero, Louisiana, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Bel Air, Maryland, United States
Pfizer Investigational Site
Columbia, Maryland, United States
Pfizer Investigational Site
Towson, Maryland, United States
Pfizer Investigational Site
Westminster, Maryland, United States
Pfizer Investigational Site
Abington, Massachusetts, United States
Pfizer Investigational Site
Haverhill, Massachusetts, United States
Pfizer Investigational Site
Natick, Massachusetts, United States
Pfizer Investigational Site
Grand Rapids, Michigan, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Billings, Montana, United States
Pfizer Investigational Site
Butte, Montana, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Papillon, Nebraska, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Concord, New Hampshire, United States
Pfizer Investigational Site
Lebanon, New Hampshire, United States
Pfizer Investigational Site
Manchester, New Hampshire, United States
Pfizer Investigational Site
Elmer, New Jersey, United States
Pfizer Investigational Site
Haddon Heights, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Garden City, New York, United States
Pfizer Investigational Site
New Hyde Park, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Mansfield, Ohio, United States
Pfizer Investigational Site
Sandusky, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Beaver, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Plano, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Burlington, Vermont, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Burien, Washington, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Concord, New South Wales, Australia
Pfizer Investigational Site
East Gosford, New South Wales, Australia
Pfizer Investigational Site
St Leonards, New South Wales, Australia
Pfizer Investigational Site
Wollongong, New South Wales, Australia
Pfizer Investigational Site
Chermside, Queensland, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Woolloongabba, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia
Pfizer Investigational Site
Woodville, South Australia, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Fitzroy, Victoria, Australia
Pfizer Investigational Site
Footscray, Victoria, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Prahran, Victoria, Australia
Pfizer Investigational Site
Fremantle, Western Australia, Australia
Pfizer Investigational Site
Joondalup, Western Australia, Australia
Pfizer Investigational Site
Camperdown, Australia
Pfizer Investigational Site
Darlinghurst, Australia
Pfizer Investigational Site
Geelong, Australia
Pfizer Investigational Site
Launceston, Tas, Australia
Pfizer Investigational Site
Melbourne, Australia
Pfizer Investigational Site
Nedlands, Australia
Pfizer Investigational Site
Perth, Australia
Pfizer Investigational Site
Southport, Australia
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Cornwall, Ontario, Canada
Pfizer Investigational Site
Newmarket, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Scarborough Village, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Sainte-Foy, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Pfizer Investigational Site
St. John's, Canada
Pfizer Investigational Site
's-Hertogenbosch, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
AN Rotterdam, Netherlands
Pfizer Investigational Site
Apeldoorn, Netherlands
Pfizer Investigational Site
Arnhem, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Cappelle Aan Den IJssel, Netherlands
Pfizer Investigational Site
Delft, Netherlands
Pfizer Investigational Site
Eindhoven, Netherlands
Pfizer Investigational Site
Goes, Netherlands
Pfizer Investigational Site
Gouda, Netherlands
Pfizer Investigational Site
Groningen, Netherlands
Pfizer Investigational Site
Heerlen, Netherlands
Pfizer Investigational Site
Hoorn, Netherlands
Pfizer Investigational Site
Leiden, Netherlands
Pfizer Investigational Site
Maastricht, Netherlands
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
Rotterdam, Netherlands
Pfizer Investigational Site
Sittard, Netherlands
Pfizer Investigational Site
Utrecht, Netherlands
Pfizer Investigational Site
Velp, Netherlands
Pfizer Investigational Site
Venlo, Netherlands
Pfizer Investigational Site
Zoetermeer, Netherlands
Pfizer Investigational Site
Almería, Almeria, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Sant Coloma de Gramenet, Barcelona, Spain
Pfizer Investigational Site
Terrassa, Barcelona, Spain
Pfizer Investigational Site
Jerez de la Frontera, Cadiz, Spain
Pfizer Investigational Site
Santander, Cantabria, Spain
Pfizer Investigational Site
Ciudad Real, Ciudad Real, Spain
Pfizer Investigational Site
Granada, Granada, Spain
Pfizer Investigational Site
Donostia / San Sebastian, Guipuzcoa, Spain
Pfizer Investigational Site
Ferrol, La Coruna, Spain
Pfizer Investigational Site
Santiago de Compostela, La Coruña, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Málaga, Malaga, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Zaragoza, Zaragoza, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Salamanca, Spain
Pfizer Investigational Site
Borås, Sweden
Pfizer Investigational Site
Eskilstuna, Sweden
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Hässleholm, Sweden
Pfizer Investigational Site
Helsingborg, Sweden
Pfizer Investigational Site
Karlshamn, Sweden
Pfizer Investigational Site
Köping, Sweden
Pfizer Investigational Site
Linköping, Sweden
Pfizer Investigational Site
Luleå, Sweden
Pfizer Investigational Site
Lund, Sweden
Pfizer Investigational Site
Malmo, Sweden
Pfizer Investigational Site
Mölndal, Sweden
Pfizer Investigational Site
Norrköping, Sweden
Pfizer Investigational Site
Östersund, Sweden
Pfizer Investigational Site
Skellefteå, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
Uddevalla, Sweden
Pfizer Investigational Site
Uppsala, Sweden
Pfizer Investigational Site
Vaxjo, Sweden
Pfizer Investigational Site
Västervik, Sweden
Pfizer Investigational Site
Wrexham, Clwyd, United Kingdom
Pfizer Investigational Site
Woolwich, London, United Kingdom
Pfizer Investigational Site
Glasgow, Scotland, United Kingdom
Pfizer Investigational Site
Aberdeen, United Kingdom
Pfizer Investigational Site
Bath, United Kingdom
Pfizer Investigational Site
Birmingham, United Kingdom
Pfizer Investigational Site
Bournemouth, United Kingdom
Pfizer Investigational Site
Brighton, East Sussex, United Kingdom
Pfizer Investigational Site
Bristol, United Kingdom
Pfizer Investigational Site
Cardiff, United Kingdom
Pfizer Investigational Site
Chichester, United Kingdom
Pfizer Investigational Site
Coventry, United Kingdom
Pfizer Investigational Site
Dundee, United Kingdom
Pfizer Investigational Site
Edinburgh, United Kingdom
Pfizer Investigational Site
Exeter, United Kingdom
Pfizer Investigational Site
Glasgow, United Kingdom
Pfizer Investigational Site
Harrow, United Kingdom
Pfizer Investigational Site
Leicester, United Kingdom
Pfizer Investigational Site
Liverpool, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
Newcastle upon Tyne, United Kingdom
Pfizer Investigational Site
Romford, United Kingdom
Pfizer Investigational Site
Shrewsbury, United Kingdom
Pfizer Investigational Site
Warwick, United Kingdom
Related Publications (8)
Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12.
PMID: 29103916DERIVEDWilliams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Circulation. 2018 Mar 6;137(10):999-1010. doi: 10.1161/CIRCULATIONAHA.117.028213. Epub 2017 Oct 3.
PMID: 28974520DERIVEDBagdade J, Barter P, Quiroga C, Alaupovic P. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). Am J Cardiol. 2017 Jun 1;119(11):1753-1756. doi: 10.1016/j.amjcard.2017.02.049. Epub 2017 Mar 18.
PMID: 28431663DERIVEDBarter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18.
PMID: 21804130DERIVEDDogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132.
PMID: 20645885DERIVEDDogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and 2 Study Groups. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb. 2010 May;17(5):526-35. doi: 10.5551/jat.3269. Epub 2010 Mar 13.
PMID: 20228610DERIVEDVergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24.
PMID: 19029469DERIVEDBarter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5.
PMID: 17984165DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 22, 2005
First Posted
August 24, 2005
Study Start
July 1, 2004
Primary Completion
June 1, 2007
Study Completion
June 1, 2007
Last Updated
February 3, 2012
Record last verified: 2012-01